Last week, pharmaceutical giant Novartis paid $51 million to settle a Massachusetts suit about patient copay waivers. The DOJ press release notes that this is the 14th settlement of this kind to come from the Boston area. In related news, the Government brought a suit against Regeneron alleging that the company had a scheme of very well calculated charitable giving that steered patients to its macular degeneration drug, which costs $1,850 per dose, and away from a competitor’s drug, which costs $55 per dose.
We are joined this week by Mary Inman, Esq. who has the latest on the Novartis suit and the FCA Allegations and how the court rules might have expensive ripple effects on the industry, and on drug prices.
Other segments to be featured during the live weekly Internet radio broadcast include the following:
Last week, pharmaceutical giant Novartis paid $51 million to settle a Massachusetts suit about patient copay waivers. The DOJ press release notes that this is the 14th settlement of this kind to come from the Boston area. In related news, the Government brought a suit against Regeneron alleging that the company had a scheme of very well calculated charitable giving that steered patients to its macular degeneration drug, which costs $1,850 per dose, and away from a competitor’s drug, which costs $55 per dose.
We are joined this week by Mary Inman, Esq. who has the latest on the Novartis suit and the FCA Allegations and how the court rules might have expensive ripple effects on the industry, and on drug prices.
Other segments to be featured during the live weekly Internet radio broadcast include the following: